NCT00285142已完成不适用
Assessment of the Effect of Rosiglitazone on Insulin Secretion in Healthy Volunteers
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- insulin response and insulin sensitivity assessed by 2-hours 10 mmol/l hyperglycemic clamp, started 45 min after treatment intake
研究概览
简要总结
To evaluate :
- acute effects of a single dose of 8 mg rosiglitazone (therapeutic dose)
- on insulin secretion and
- insulin sensitivity in 12 healthy male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •BMI between 18.0 and 24.0
排除标准
- 未提供
结局指标
主要结局
insulin response and insulin sensitivity assessed by 2-hours 10 mmol/l hyperglycemic clamp, started 45 min after treatment intake
次要结局
- insulin clearance
- tolerance
- basal glycemia and insulinemia
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
Glitazones and Endothelial Function (GATE)Diabetes MellitusNCT00203632University of Calgary40
撤回
4 期
Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With AnginaAngina PectorisDiabetes Mellitus, Type 2NCT00225342University of Glasgow60
终止
4 期
Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty LiverChronic Hepatitis C InfectionFatty LiverNCT00274495Beth Israel Medical Center30
终止
4 期
Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASHNASH (Non-alcoholic Steato-hepatitis)NCT01406704Seoul St. Mary's Hospital26
已完成
2 期
Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II DiabetesCongestive Heart FailureNCT00064727National Heart, Lung, and Blood Institute (NHLBI)50